Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.51 |
| ▸ | FNTB | P49356 | 10/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740245 | 1.00 | FNTA (0.51) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8574812 | 0.92 | PARP1 (0.51) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8574809 | 0.92 | PARP1 (0.51) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8453364 | 0.91 | FNTA (0.59) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8453359 | 0.91 | FNTA (0.59) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8390112 | 0.90 | FNTA (0.62) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8390110 | 0.90 | FNTA (0.62) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8576632 | 0.89 | FNTA (0.57) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8572832 | 0.89 | FNTA (0.49) | FNTAFNTBPARP1PGGT1BALDH1A1 | |
| SCHEMBL8572840 | 0.89 | FNTA (0.49) | FNTAFNTBPARP1PGGT1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087981-B1 | PRENYL TRANSFERASE INHIBITORS | SOD CONSEILS RECH APPLIC (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-6313109-B2 | ANTIPROLIFERATIVE AGENTS; TREATING TUMORS, RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2001-11-06 | — | — | US | disclosed |
| US-20010000344-A1 | Prenyl transferase inhibitors | BIOMEASURE INCORPORATED | 2001-04-19 | — | — | US | disclosed |
| US-6180619-B1 | TREATING TUMORS OR RESTENOSIS | BIOMEASURE, INCORPORATED | 2001-01-30 | — | — | US | disclosed |
| US-5929077-A | Thioproline-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 1999-07-27 | — | — | US | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000344-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885PARP1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.